Clinical Trial Update: Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating orelabrutinib combined with low-dose radiotherapy or rituximab for marginal zone lymphoma of the ocular adnexa; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma of the Ocular Adnexa

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Marginal Zone Lymphoma of Ocular Adnexal, Marginal Zone Lymphoma(MZL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING